<DOC>
	<DOCNO>NCT02291432</DOCNO>
	<brief_summary>To study safety autologous muscle-derived cell ( AMDC ) treatment male stress urinary incontinence ( SUI ) patient undergone prior prostate surgery .</brief_summary>
	<brief_title>Autologous Cell Therapy Stress Urinary Incontinence Males Following Prostate Surgery</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Urination Disorders</mesh_term>
	<mesh_term>Urological Manifestations</mesh_term>
	<criteria>Male , least 18 year old , primary symptom SUI follow prostate surgery , Patient undergone prostate surgery undergone radiation therapy , cryotherapy , highintensity focus ultrasound prostate , SUI severity â‰¥10 g &lt; 400 g urine leakage 24 hour , Patient fail achieve acceptable resolution SUI symptom follow prior therapy . Symptoms urge urinary incontinence , Symptoms stress urinary incontinence prior prostate surgery , Routinely 2 episode awaken void normal sleeping hour , Compromised immune system due disease state , chronic corticosteroid use , immunosuppressive therapy , Previously treat periurethral balloon adjustable sling urinary incontinence , Symptoms overflow incontinence Additional medical restriction specify Clinical Investigation Plan , Additional anatomical restriction specify Clinical Investigation Plan .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>